Announcements Trials

Browse Landscape

Phase

Phase 3 2 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 295 Carcinoma, Non-Small-Cell Lung 160 Lung Neoplasms 89 Breast Neoplasms 84 Urinary Bladder Neoplasms 83 Cholangiocarcinoma 58 Neoplasms 53 Neoplasm Metastasis 51 Ovarian Neoplasms 45 Biliary Tract Neoplasms 45 Lymphoma, Large B-Cell, Diffuse 32 Lymphoma 30 Sarcoma 29 Hodgkin Disease 28 Recurrence 26 Nasopharyngeal Carcinoma 26 Gallbladder Neoplasms 26 Carcinoma, Transitional Cell 26 Adenocarcinoma 22 Triple Negative Breast Neoplasms 20 Fallopian Tube Neoplasms 20 Bile Duct Neoplasms 20 Adenocarcinoma of Lung 20 Carcinoma, Renal Cell 17 Carcinoma, Ovarian Epithelial 16 Urethral Neoplasms 15 Lymphoma, Non-Hodgkin 15 Colorectal Neoplasms 14 Leiomyosarcoma 13 Kidney Neoplasms 13

Interventions

Docetaxel 5 S 1 (combination) 2 Carboplatin 2 zimberelimab 1 surufatinib 1 quemliclustat 1 pemigatinib 1 nimotuzumab 1 lorlatinib 1 cemiplimab 1 Vinorelbine 1 Pemetrexed 1 Paclitaxel 1 Gene Expression Profiling 1 Gemcitabine 1 Erlotinib Hydrochloride 1 Cetuximab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Advanced Non-Small Cell Lung Cancer × Gemcitabine × Clear all

NCT00330746 2012-05-18

CALC-1

National Cancer Institute, Naples

Phase 2 Completed

Advanced Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡